BioTuesdays
Profound

Paradigm ups Profound Medical PT to C$45

Paradigm Capital raised its price target for Profound Medical (TSX:PRN; NASDAQ:PROF) to C$45 from C$40 based on the company’s commercialization plan for TULSA-PRO. The stock closed at $12.70 on the TSX on Nov. 5...

PDS Biotechnology

HCW starts PDS Biotechnology at buy; PT $7

H.C. Wainwright initiated coverage of PDS Biotechnology (NASDAQ:PDSB) with a “buy” rating and $7 price target. The stock closed at $3.05 on Nov. 4. PDS is developing anti-cancer therapeutics leveraging its proprietary...

Sientra

WB ups Sientra to OP

William Blair upgraded Sientra (NASDAQ:SIEN) to “outperform,” saying the company’s near-to-midterm outlook has stabilized and is improving. The stock closed at $6.77 on Nov. 4. Analyst Margaret Kaczor writes that she...

HCW starts aTyr Pharma at buy; PT $8

H.C. Wainwright launched coverage of aTyr Pharma (NASDAQ:LIFE) with a “buy” rating and $8 price target. The stock closed at $3.73 on Nov. 4. aTyr is developing therapies leveraging resokines, naturally occurring...

Agile Therapeutics

WB ups Agile Therapeutics to OP

William Blair upgraded Agile Therapeutics (NASDAQ:AGRX) to “outperform” after an FDA advisory committee voted overwhelmingly to approve its resubmitted NDA for the Twirla transdermal combined hormonal contraceptive...

Oyster Point Pharma prices $80-millon IPO

Oyster Point Pharma (NASDAQ:OYST) priced an initial public offering of five million common shares at a price of $16 each to raise gross proceeds of $80-million. The offering is expected to close on Nov. 4. The company...

Subscribe

Sign up to our weekly BioTuesdays newsletter.